



Published in final edited form as:

J Allergy Clin Immunol. 2010 June ; 125(6): 1389–1390. doi:10.1016/j.jaci.2010.01.047.

Invasive fungal disease in autosomal-dominant hyper-IgE syndrome

Donald C. Vinh, M.D.^{1,*}, Janyce A. Sugui, Ph.D.², Amy P. Hsu, B.A.¹, Alexandra F. Freeman, M.D.¹, and Steven M. Holland, M.D.¹

¹ Immunopathogenesis Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

² Molecular Microbiology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

Abstract

We demonstrate that autosomal-dominant *STAT3*-deficient hyper-IgE syndrome confers late-onset susceptibility to molds, especially *Aspergillus*, despite preserved myeloid functions, in association with previous parenchymal lung damage (bronchiectasis/pneumatoceles). This suggests a critical role for non-hematopoietic processes in innate antifungal immunity in AD-HIES.

Keywords

autosomal dominant hyper-IgE syndrome; *STAT3*; fungus; aspergillus; aspergillosis

To the Editor:

Autosomal-dominant hyper-IgE (Job's) syndrome (AD-HIES), due to heterozygous dominant-negative mutations in *STAT3*, is characterized by staphylococcal skin abscesses, eczematous dermatitis, connective tissue defects and elevated serum IgE[1,2]. Recurrent bacterial pneumonias, attributed to dysfunctional *STAT3*, frequently lead to bronchiectasis and formation of pneumatoceles. Fungal pneumonias, particularly aspergillosis, have also been reported in patients diagnosed with AD-HIES, albeit by clinical scoring system, and are a cause of mortality[3]. However, the few reports of invasive mycoses in patients with HIES pre-dated the ability to genotypically confirm the patients' diagnoses, potentially admixing heterogeneous phenocopies and precluding comprehensive understanding of fungal disease in AD-HIES. We sought to define the epidemiology of invasive mycoses in patients with confirmed *STAT3*-mutant AD-HIES. Further, since *STAT3* is implicated in multiple hematopoietic and non-hematopoietic processes, and the former are critical to antifungal resistance in other at-risk groups, we evaluated myeloid function related to fungal susceptibility.

*Corresponding Author: 9000 Rockville Pike, Bldg 10CRC, Room B3-4141, MSC 1684, Bethesda, MD USA, 20892. Phone: 301-496-2473; Fax: 301-480-4507; vinhd@niaid.nih.gov.

Potential conflicts of interest: none to declare

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Medical records of all patients with the diagnosis of AD-HIES enrolled on protocols of the National Institute of Allergy and Infectious Diseases, NIH and confirmed by *STAT3* sequencing [2] were reviewed. Patients with clinical, computed tomography (CT), and laboratory evidence of “proven” and “probable” invasive fungal disease, based on EORTC/MSG consensus definitions[4], were identified.

Sixty-four *STAT3* AD-HIES patients were identified: 23 (36%) had no CT evidence of lung bronchiectasis/cysts/cavities/pneumatoceles, while 41 (64%) did. Of those without lung damage, none had concurrent or previous invasive mycoses. Among the 41 patients with parenchymal lung defects, 18 (44%) had at least 1 episode of invasive mold disease, typically involving the respiratory tract. Thus overall, 28.1% of all patients developed an invasive mycosis. The isolated molds were *Aspergillus* spp. (n=16; 83.3%), *Scedosporium apiospermum* (n=2), and *Histoplasma capsulatum* (n=2). One patient had aspergillosis and subsequently *S. apiospermum*; another had laryngeal histoplasmosis followed by aspergillosis. The other case of histoplasmosis manifested as a tongue ulcer with right middle lobe lung involvement necessitating lobectomy. Mold disease did not solely manifest as “fungus balls” restricted to lung cavities but also as consolidations without halo sign (Figure 1); 5 patients had disseminated disease. Two cases due to the yeast, *Cryptococcus* sp., presented as an esophageal mass[6] and meningitis, respectively; both occurred in patients with abnormal lung.

Stratification of patients based on location of *STAT3* mutation (DNA-binding domain vs. SH2 domain) was performed to identify any genotype-phenotype correlation in regards to the development of fungal infections (Table). The occurrence of structural lung disease, fungal disease, median age of onset of first fungal pneumonia, and mortality due to fungal infection were not statistically different between domains (Fisher’s exact test). Treatment was variable (systemic antifungal therapy, with/without intracavitary instillation of antifungals or surgical resection). Overall, mortality rate among those who developed fungal disease was 16.7%.

The integrity of myeloid functions associated with susceptibility to invasive mycoses was investigated. Neutrophils, peripheral blood mononuclear cells (PBMC), and plasma were isolated from patients (3 AD-HIES; 3 CGD) and healthy donors (n=4), and *Aspergillus fumigatus* B-5233, a pulmonary isolate from a leukemia patient, was prepared, as previously described[5]. Patients’ neutrophils were previously investigated for reactive oxygen species production via nitroblue tetrazolium histochemical staining, cytochrome c reduction, and dihydrorhodamine-123 flow cytometry; no deficiency was detected in the AD-HIES patients. The capacities of neutrophils or PBMC to inhibit growth of *Aspergillus* swollen conidia (the earliest metabolically-active spore form) and of germlings (the earliest hyphal form) in autologous plasma were assessed by modified XTT method at leukocyte:fungus ratios of 0, 0.5, 1 and 2[5]. This method has previously been used to demonstrate that neutrophils from patients with chronic granulomatous disease (CGD) have impaired ability to control *A. fumigatus* germlings[5], recapitulating the *in vivo* phenomenon. Data analysis was performed using GraphPad Prism software (v.5).

Swollen conidia were inhibited equally well by neutrophils from controls and patients (data not shown). Neutrophils from AD-HIES patients inhibited the growth of germlings as effectively as normal donors, whereas neutrophils from CGD patients were significantly less effective (Figure 2). PBMC from controls and patients equally suppressed swollen conidia but mediated no significant inhibition of germlings at ratios tested (data not shown).

Among primary immunodeficiencies, only 2 demonstrate consistent susceptibility to invasive aspergillosis: CGD and AD-HIES. The former results from mutations in the phagocyte NADPH oxidase complex, impairing their ability to generate reactive oxygen species. Consequently, patients with CGD demonstrate high frequency of invasive aspergillosis (25–

35%), whereby fungal disease typically occurs within the first 2 decades of life in otherwise normal lung. AD-HIES patients are also at risk for invasive mold infections (28% of this cohort), most commonly *Aspergillus*. In contrast to CGD, invasive fungal disease typically occurred in the fourth decade of life and only when there were concurrent anatomical lung defects from previous bacterial pneumonias. Despite therapy, mortality from invasive fungal disease was significant (~17%).

Late-onset invasive fungal disease in the setting of anatomical lung defects suggests that susceptibility to molds in AD-HIES is distinct from that in CGD. In agreement with this hypothesis, leukocytes from AD-HIES patients performed as well as those from healthy donors in *in vitro* killing of *Aspergillus* conidia and hyphae and markedly better than CGD, suggesting that an intrinsic myeloid defect is not the prime reason these patients are susceptible to molds. Furthermore, chemotaxis of AD-HIES neutrophils towards *A. fumigatus* was not different from controls (Supplemental videos). Therefore, *STAT3* mutations do not appear to impair the capacity of neutrophils or PBMC to inhibit *Aspergillus in vitro*. However, *STAT3* may be operational in the myeloid control of intracellular fungi (e.g. *Histoplasma*).

STAT3 enables the epithelium to respond to Th17-based cytokines by upregulating antimicrobial peptides; defects in this pathway likely account for susceptibility to bacterial infections[7]. *STAT3* also has numerous roles in lung processes relevant to epithelial integrity following injury[8,9], such as bacterial infection; defects in these healing processes likely create a nidus for subsequent susceptibility to fungal pneumonias, similar to cystic fibrosis or post-tuberculosis cavities.

AD-HIES confers a significant late-onset risk of invasive fungal disease despite preserved myeloid functions. This temporally-dynamic susceptibility is associated with bronchiectasis/pneumatoceles, likely related to *STAT3*'s role in lung epithelial homeostasis and defense.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Sources of financial support: Canadian Institutes of Health Research (CIHR); Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH

References

1. Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of *STAT3* cause hyper-IgE syndrome. *Nature* 2007;448:1058–62. [PubMed: 17676033]
2. Holland SM, DeLeo FR, Elloumi HZ, et al. *STAT3* Mutations in the Hyper-IgE Syndrome. *N Engl J Med* 2007;357:1608–1619. [PubMed: 17881745]
3. Freeman AF, Kleiner D, Nadiminti H, et al. Causes of death in hyper-IgE syndrome. *J Allergy Clin Immunol* 2007;119:1234–40. [PubMed: 17335882]
4. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. *Clin infect dis* 2008;46:1813–1821. [PubMed: 18462102]
5. Zarembek KA, Sugui JA, Chang YC, Kwon-Chung KJ, Gallin JI. Human Polymorphonuclear Leukocytes Inhibit *Aspergillus fumigatus* Conidial Growth by Lactoferrin-Mediated Iron Depletion. *J Immunol* 2007;178:6367–6373. [PubMed: 17475866]

6. Jacobs DH, Macher AM, Handler R, Bennett JE, Collen MJ, Gallin JI. Esophageal cryptococcosis in a patient with the hyperimmunoglobulin E-recurrent infection (Job's) syndrome. *Gastroenterology* 1984;87:201–3. [PubMed: 6373479]
7. Minegishi Y, Saito M, Nagasawa M, et al. Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. *J Exp Med* 2009;206:1291–1301. [PubMed: 19487419]
8. Matsuzaki Y, Xu Y, Ikegami M, et al. Stat3 Is Required for Cytoprotection of the Respiratory Epithelium during Adenoviral Infection. *J Immunol* 2006;177:527–537. [PubMed: 16785550]
9. Kida H, Mucenski ML, Thitoff AR, et al. GP130-STAT3 Regulates Epithelial Cell Migration and Is Required for Repair of the Bronchiolar Epithelium. *Am J Pathol* 2008;172:1542–1554. [PubMed: 18467707]




Figure 1.
CT of invasive fungal pneumonia in AD-HIES.




Figure 2. Growth inhibition of *A. fumigatus* hyphae by neutrophils from AD-HIES patients compared to normal donors and CGD patients.

TableClinical characteristics of invasive fungal disease in AD-HIES patients based on location of *STAT3* mutation

	Mutation in DNA-binding domain	Mutation in SH2-binding domain
Number of patients	34	30
Frequency of patients with structural lung disease	23 (67.6%)	18 (60%)
Frequency of patients with invasive fungal disease	10 (29.4%)*	8 (26.7%)*
Median age of onset of first fungal pneumonia (years)	32	30
Mortality due to invasive fungal disease	3	0

* All cases occurred in patients with structural lung disease